Gastrointestinal Stromal Tumors News and Research

RSS
Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

UCSD researchers define epidemiology of gastrointestinal stromal tumors

UCSD researchers define epidemiology of gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines closes $25 million Series B financing

Scientists prevent cell sleep to reduce chance of tumor recurrence

Scientists prevent cell sleep to reduce chance of tumor recurrence

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

ARIAD Pharmaceuticals initiates ponatinib Phase 2 trial in adult patients with metastatic GIST

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Bayer receives FDA approval for Stivarga to treat advanced gastrointestinal stromal tumors

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

Gastrointestinal Cancers Symposium to be held from Jan. 24-26 in San Francisco, CA

Regorafenib phase III results strongly support use in GIST

Regorafenib phase III results strongly support use in GIST

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

AB Science announces data from development program of masitinib in GIST

AB Science announces data from development program of masitinib in GIST

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx announces data from regorafenib Phase 3 trial on GIST

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

Beneficial design element in sunitinib phase III clinical trial for gastrointestinal stromal tumors

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx announces results from regorafenib Phase 3 trial on GIST